CD86 and ovarian neoplasm: However, even with these limits, we observed that the treatment of humanized ovarian tumor-bearing mice by murlentamab monotherapy tended to increase CD86+ blood cells and strongly decreased CD163+ blood cells (Figure 5D), signing a monocyte/macrophage orientation towards an M1 anti-tumor profile.